MedTrace Logo

S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy

NCT02191566 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2022-12-08

No results posted yet for this study

Summary

After curative resection, patients with stage IIIB-IV (M0) gastric cancer were given chemotherapy as follows: S-1 orally at 80 mg/m2 divided in two daily doses for 14 days and oxaliplatin at 130 mg/m2 intravenously over 2 h every 21 days as one cycle. S1 was administered for 16 cycles (12 months) and oxaliplatin for 8 cycles (6 months).

Conditions

  • Stomach Cancer

Interventions

DRUG

S-1 (452500ACH)

S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months

DRUG

OXALIPLATIN (205803BIJ)

Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months

Sponsors & Collaborators

  • Kangbuk Samsung Hospital

    lead OTHER

Principal Investigators

  • Dong Hoe Koo, MD,PhD · Kangbuk Samsung Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191566 on ClinicalTrials.gov